º£½ÇÉçÇø

After its dividend cut and the prospect of a slow recovery, Shell's proposition for investors looks far weaker

Beyond fighting Covid-19, the group’s expertise lies in eye disease and cancer treatment

Thanks to its long-term, contracted revenues and acquisition strategy, the group increased its dividend by 10 per cent in 2019 and aims to repeat that feat this year

RIT Capital Partners has a good record of preserving wealth and has recently fallen from a high premium

Shedding tears over that Boohoo ESG play

When managers move to a new firm they do not necessarily replicate their former success

With earnings underpinned by its long-standing relationship with the UK Ministry of Defence, the group is expanding its international presence

Slimming down into a more focused group, with blockbuster drug ‘Keytruda’ at the helm

With defendable margins and steady top-line growth, the pensions advisory business looks less risky than most stocks out there

The group is starting to recover from the shock of coronavirus